merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>N/A</answer>
<question_number>2</question_number>
<answer>By selling lower-cost Zepbound vials directly to patients</answer>
<question_number>3</question_number>
<answer>Less oversight than traditionally approved medications</answer>
<question_number>4</question_number>
<answer>To regain market share from telehealth companies offering compounded versions</answer>
<question_number>5</question_number>
<answer>Allows compounding pharmacies to make copycat versions</answer>
<question_number>6</question_number>
<answer>Removing third-party supply chain entities</answer>
<question_number>7</question_number>
<answer>Appeal to people on Medicare</answer>
<question_number>8</question_number>
<answer>By positioning its vials as a safer option</answer>
<question_number>9</question_number>
<answer>"in shortage"</answer>
<question_number>10</question_number>
<answer>Lower pricing</answer>